Skip to main navigation
TCR2 Staging

Corporate Menu & Investor Relations

Contact Patients
Mission Leadership Community
The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications
Overview TC-210 TC-110 Pipeline
Press Releases In the News Awards
Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs
Careers
investors.jpg
TCR2 Investors

Corporate Menu & Investor Relations

About Us Mission Leadership Community Technology The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications Programs Overview TC-210 TC-110 Pipeline News Press Releases In the News Awards Investors Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs Careers Careers Contact Patients

Press Releases

Latest Press Releases | In The News

Press Releases

All News | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Mar 03, 2021

TCR² Therapeutics to Participate in Two Upcoming Conferences in March


Feb 17, 2021

TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference


Feb 04, 2021

TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors


Jan 19, 2021

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock


Jan 19, 2021

TCR² Therapeutics Announces Proposed Public Offering of Common Stock


Jan 08, 2021

TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones


Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
TCR2
 

100 Binney Street, Suite 710
Cambridge, MA 02142
617.949.5200

TERMS OF USE

Corporate Menu & Investor Relations

About Us
Technology
Programs
News
Investors
Careers
Contact
Patients